• Acorda Therapeutics Inc (NASDAQ: ACOR) announced that Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany.

• INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor. 

• Under the distribution and supply agreements, Acorda will receive a significant double-digit percentage of the selling price of INBRIJA in Germany in exchange for the supply of the product and will receive additional sales-based milestones.

• Acorda expects to start receiving revenue from the product supply during Q2 of 2022.

• Acorda had also previously announced an agreement with Esteve to commercialize INBRIJA in Spain with a commercial launch in early 2023 and an agreement with Biopas Laboratories to commercialize INBRIJA in Latin America.

• The company is in active discussions with additional companies for the rights to distribute INBRIJA in other countries.

• Price Action: ACOR shares are up 37.40% at $0.55 during the premarket session on the last check Thursday.

See more from Benzinga

• Checkpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients

• Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.